Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Shareholder vote
confidence 95%
filed 2026-08-17
Item 5.07
Silo Pharma held its annual shareholder meeting on August 14, 2026, with voting results on four proposals: election of four directors (all approved), ratification of Salberg & Company as auditor (approved), authorization to increase authorized common shares from 6.67 million to 250 million shares (approved with 498,224 votes for and 190,599 against), and meeting adjournment authority (approved). The substantial increase in authorized shares represents a material expansion of the company's equity issuance capacity and potential dilution.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-08-17
The 6-K furnishes a "Consolidated Synthetic remote voting map" disclosing the results of an Extraordinary General Meeting held on August 18, 2026. The document presents voting tallies on seven items including the number of Board members, nomination and election of directors (Daniel Barriuso Rojo and Gilson Finkelsztain), and confirmation of Board composition. This is a direct disclosure of shareholder vote results as required by CVM Resolution No. 81/22, matching the `shareholder_vote_results` taxonomy type.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-08-17
The filing discloses results of a Special Meeting of stockholders held on August 13, 2026, where shareholders voted on a Charter Amendment Proposal to extend the Business Combination Period by nine months (from August 18, 2026 to May 18, 2027). The proposal received 3,904,200 affirmative votes representing 96.1% of outstanding shares, exceeding the 65% approval threshold required. Item 5.07 explicitly reports submission of matters to a vote of security holders and the voting results.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-17
Item 5.07
This Item 5.07 disclosure reports the results of CEL-SCI's annual shareholder meeting held on August 14, 2026, including election of three directors (Geert Kersten, Bruno Baillavoine, Robert Watson) and approval of six proposals: adoption of the 2026 Non-Qualified Stock Option Plan, adoption of the 2026 Stock Bonus Plan, advisory vote on executive compensation, advisory vote frequency, and ratification of BDO USA, LLP as independent auditor. The tabulation of votes cast for each proposal is provided in full, which is the core disclosure required by Item 5.07.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-14
Item 5.07
This Item 5.07 disclosure reports the results of CytoSorbents' 2026 Annual Meeting of Stockholders held on August 13, 2026, including voting outcomes on five proposals: election of five directors, advisory approval of named executive officer compensation, ratification of the independent auditor (WithumSmith+Brown, PC), approval of a reverse stock split (1-for-5 to 1-for-20 ratio), and approval of an adjournment provision. All proposals passed. The disclosure includes detailed vote tallies (For, Against, Abstain, Broker Non-Votes) for each proposal, which is the standard format for shareholder vote results under Item 5.07.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 97%
filed 2026-08-14
Item 5.07
RE/MAX Holdings shareholders approved two material merger proposals at a special meeting held on August 14, 2026: approval of issuance of Class A common stock to RIHI stockholders (26,660,357 votes for, 169,623 against) and adoption of the Merger Agreement with The Real Brokerage Inc. (26,681,107 votes for, 149,866 against), creating the combined 'Real REMAX Group' entity. Shareholders of both Real and RE/MAX Holdings approved the transaction, with Real shareholders voting approximately 99.0% in favor and RE/MAX Holdings shareholders voting 78.8% of voting power in favor.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-14
Item 5.07
PDS Biotechnology held its Annual Meeting of Stockholders with voting results on four proposals: election of two Class B directors (Kamil Ali-Jackson and Ilian Iliev), approval of a Certificate of Incorporation amendment to increase authorized common shares, ratification of KPMG as independent auditor, and a non-binding advisory vote on named executive officer compensation.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-08-14
The 6-K discloses results of an Extraordinary General Meeting held on August 14, 2026, where shareholders voted on and approved two material proposals: (1) a 1-for-5 consolidation of Class A and Class B ordinary shares, and (2) authorization for a further consolidation at a ratio between 1-for-2 and 1-for-10 to be determined by the board by February 10, 2027. The filing provides detailed voting tallies for each proposal, including vote counts and percentages for both share classes. This is a classic shareholder vote result disclosure under Item 5.07 equivalent, and the share consolidation is material to investors as it affects share structure and ownership percentages.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-08-14
The filing discloses results of a Special Meeting of Stockholders held on August 13, 2026, where shareholders voted on two proposals: (1) approval of a reverse stock split authorization (1-for-2 to 1-for-8 ratio, to be determined by the Board), which passed with 49,401,476 votes for vs. 10,935,417 against, and (2) an adjournment proposal, which also passed. This is a classic Item 5.07 shareholder vote results disclosure. The reverse stock split authorization is material to investors as it affects share structure and is typically undertaken to address delisting risks or improve stock price perception.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-08-14
The filing discloses Item 5.07 results from a special stockholder meeting held on August 14, 2026, where shareholders voted on a reverse stock split proposal (approved 3,847,974 to 1,062,981) and an adjournment proposal. The reverse stock split authorization at a 1-for-2 to 1-for-50 ratio is material to investors as it directly affects share structure and is typically a signal of delisting risk mitigation or capital restructuring.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-08-14
The filing discloses Item 5.07 — submission of matters to a vote of security holders. The Majority Stockholder (Rennova Health, Inc., controlled by the CEO) approved by written consent an amendment to the Certificate of Incorporation authorizing a reverse stock split at a ratio of 1:50 to 1:1,000, with the exact ratio to be determined by the Board solely for purposes of facilitating an uplisting to Nasdaq or NYSE American. This is a material shareholder action affecting capital structure and listing status.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-08-14
The filing discloses results of GT Biopharma's Annual Meeting of Stockholders held on August 14, 2026, under Item 5.07. Six proposals were voted upon: election of four directors, ratification of auditors (Weinberg & Company, P.A.), advisory approval of executive compensation, approval of a reverse stock split (1-for-10 to 1-for-30 ratio) with authorized share reduction, and two amendments to the 2022 Omnibus Incentive Plan. All proposals passed. The reverse stock split authorization and equity plan amendments are material governance and capital structure decisions affecting shareholders.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-08-14
Item 5.07 discloses the results of the 2026 Annual Meeting of Shareholders held on August 12, 2026, including voting results for the election of trustee Steven S. Robson (7,090,809 votes for) and ratification of BCRG Group as independent auditors (7,447,535 votes for). This is a standard shareholder vote results disclosure that is material to investors as it confirms board composition and auditor appointment.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-08-14
Item 5.07
This 8-K Item 5.07 discloses the results of a special meeting of stockholders held on August 13, 2026, where shareholders voted on a proposal to authorize the Company to issue shares of common stock below net asset value (up to 25% of outstanding shares) for a twelve-month period. The vote tabulation shows the proposal was approved with 287.2 million votes in favor versus 70.1 million against. This is a material shareholder vote result that grants significant capital-raising authority to management.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 25%
filed 2026-08-14
EX-99.1
This is a 2026 proxy statement soliciting shareholder votes on five proposals at the Annual General Meeting scheduled for September 18, 2026. The document is not reporting results of a vote that has already occurred; rather, it is requesting shareholder approval in advance of the meeting. The most material proposal is Proposal 4, which seeks shareholder approval to issue approximately 11.58 million new Butterfield shares (39% of the $1.794 billion purchase price) in connection with the acquisition of CIBC Caribbean. However, since this is a proxy statement soliciting votes rather than disclosing vote results, the proper classification is ambiguous—the exhibit is neither a discrete event nor a periodic report, but rather a governance document requesting shareholder action on a material M&A transaction.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-08-14
The 6-K discloses the results of an extraordinary general meeting of shareholders held on August 10, 2026, with voting outcomes on three resolutions: (1) approval of a 100x increase in authorized share capital from 50 million to 5 billion shares; (2) creation of dual-class shares (Class A with 1 vote, Class B with 50 votes) and adoption of amended articles; and (3) a 6-for-1 share consolidation effective October 7, 2026. All three resolutions passed with overwhelming majorities (99.7%+). These governance and capital structure changes are material to investors' assessment of voting rights, ownership dilution, and control dynamics.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-14
Item 5.07
Owlet held its Annual Meeting of Stockholders on June 15, 2026, and reported final voting results for five proposals: election of directors Marc F. Stoll and Kurt Workman, advisory vote on named executive officer compensation (approved), annual frequency for say-on-pay votes, ratification of PricewaterhouseCoopers LLP as auditor, and approval of Amendment No. 3 to the 2021 Incentive Award Plan increasing the equity share pool by 600,000 shares.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 92%
filed 2026-08-14
Item 5.07
Shareholders approved three proposals at a meeting: an Articles Amendment, a Trust Agreement Amendment extending the business combination deadline to February 15, 2027, and an Adjournment Proposal. The vote also resulted in 833,157 ordinary shares being redeemed, removing approximately $9.3 million from the Trust Account.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-08-13
Item 5.07
Results of the Annual Meeting of Shareholders held on August 11, 2026, including election of eight directors to the Board, advisory vote on named executive officer compensation, and ratification of PricewaterhouseCoopers, LLP as independent auditor.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 96%
filed 2026-08-13
Item 5.07
Zoomcar held its 2026 Annual Meeting of Stockholders on August 11, 2026, with stockholder approval of six proposals: ratification of auditors, authorization to increase authorized common shares from 250 million to 1.99 billion, approval of a warrant exchange offer for up to 509 million shares, a restricted stock grant to Chairman Uri Levine, authorization for a reverse stock split, and meeting adjournment. All proposals passed, reflecting material shareholder approval of significant capital structure changes and executive compensation.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-08-13
Item 5.07
FitLife Brands held its 2026 Annual Meeting of Stockholders on August 11, 2026, with shareholders electing five directors (Dayton Judd, Grant Dawson, Matt Lingenbrink, Seth Yakatan, and Shannon Pappas) and ratifying Weinberg & Company, P.A. as independent auditors.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-08-13
Item 5.07
Results of the 2026 Annual Meeting of stockholders were disclosed, with all four proposals passing: election of Mohit Daswani as a Class I director, ratification of Deloitte & Touche LLP as independent auditor, advisory approval of named executive officer compensation, and advisory vote on compensation vote frequency.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-08-13
Item 5.07
McGraw Hill disclosed the results of its August 11, 2026 annual stockholder meeting, including election of four directors (Simon Allen, Mary Ann Sigler, Guhan Subramanian, Eric Worley), advisory approval of executive compensation, determination of annual frequency for future advisory compensation votes, and ratification of Ernst & Young LLP as independent auditor.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-12
Item 5.07
PetMed Express held its Annual Meeting of Shareholders on August 11, 2026, with shareholders voting on four proposals: election of four directors, advisory approval of named executive officer compensation, ratification of Baker Tilly US, LLP as independent auditor, and approval of an amendment to the 2024 Omnibus Incentive Plan increasing the share reserve by 1,800,000 shares.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-08-12
The 6-K discloses the results of an extraordinary general meeting held on August 11, 2026, where shareholders voted on seven proposals. All proposals were approved, including a company name change from "BIT ORIGIN LTD" to "SANGRIX INC.", a massive share capital increase (from US$15,000 to US$60,000,000), a 5-for-1 share consolidation, and amendments to the memorandum of association. These are material governance and capital structure changes that would affect a reasonable investor's assessment of the registrant.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 97%
filed 2026-08-12
Item 5.07
AvalonBay stockholders approved three proposals at a Special Meeting held on August 12, 2026: (1) approval of the merger with Equity Residential (126.5M for, 51.7K against); (2) approval of merger-related compensation (125.6M for, 938.9K against); and (3) adjournment of the meeting (116.0M for, 10.5M against). All three proposals passed with overwhelming support, representing approximately 90% of outstanding shares voting in favor of the transformative merger that will create "Vivmark Residential," expected to close on August 17, 2026.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 97%
filed 2026-08-12
Item 5.07
Equity Residential shareholders voted on August 12, 2026 to approve three proposals related to the proposed merger of equals with AvalonBay Communities, including share issuance, charter amendment, and adjournment. All three proposals were approved with overwhelming majorities (>99% of votes cast), representing approximately 90% of outstanding shares, with the combined entity expected to be named Vivmark Residential and close on August 17, 2026.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-08-12
EX-99.1
This exhibit discloses the results of Himax's annual general meeting held on August 12, 2026, including shareholder adoption of 2025 audited financial statements and re-election of an independent director. The disclosure of shareholder vote outcomes at an annual meeting is a classic shareholder_vote_results event. The approval of audited financial statements and director re-election are material governance matters affecting investor assessment of the company's financial reporting and board composition.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 85%
filed 2026-08-12
Item 5.07
The filing discloses the results of the 2026 annual meeting of stockholders held on August 11, 2026, which is the core purpose of Item 5.07. Although the meeting was adjourned due to lack of quorum before voting could occur on director elections and auditor ratification, the disclosure of this outcome—including the consequence that incumbent directors will serve as holdovers under Maryland law—constitutes a shareholder vote result (or in this case, the failure to achieve one). This is material because it affects governance continuity and director accountability to shareholders.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 92%
filed 2026-08-12
Item 5.07
Stockholders approved an amendment to extend the business combination termination date from August 12, 2026 to August 12, 2027, with board discretion to extend monthly, at the August 6, 2026 annual meeting. The Extension Amendment Proposal and Adjournment Proposal each received overwhelming approval (5,913,418 FOR votes vs. 999 AGAINST). Additionally, 215,488 shares were tendered for redemption.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 98%
filed 2026-08-12
EX-99.1
This is a formal Report of Voting Results disclosing the outcomes of High Tide Inc.'s annual general and special meeting of shareholders held on August 11, 2026. The document reports voting results on four matters: (1) re-appointment of Davidson & Company LLP as auditor (99.47% for); (2) fixing the number of directors at five (97.92% for); (3) election of five director nominees (all with >97% support); and (4) ratification of a restated shareholder rights plan (91.07% for). This is a classic shareholder_vote_results disclosure required under National Instrument 51-102 Continuous Disclosure Obligations.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 98%
filed 2026-08-12
EX-99.1
This is a news release announcing the voting results from High Tide's annual general and special meeting of shareholders held on August 11, 2026. The exhibit discloses detailed vote tallies for the election of five directors (Harkirat Grover, Christian Sinclair, Arthur Kwan, Menashe Kestenbaum, and Kathleen Skerrett), fixing the board at five members, appointment of Davidson & Company LLP as auditors, and approval of an Amended and Restated Shareholder Rights Plan. These are core shareholder governance matters whose outcomes materially affect the registrant's governance structure and would affect a reasonable investor's assessment.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-08-12
Item 5.07
Results of the 2026 Annual Meeting held on August 10, 2026 disclosed the voting outcomes for three proposals: election of two Class III directors (Ixchell C. Duarte and Tatiana G. Ferreira), approval of the Amended and Restated 2021 Incentive Plan, and ratification of KPMG LLP as independent auditor.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 85%
filed 2026-08-12
The filing's primary disclosure is the results of an Extraordinary General Meeting held on August 11, 2026, where shareholders voted on two proposals: the Extension Amendment Proposal (to extend the business combination deadline by 12 months) and the Trust Agreement Amendment Proposal. Item 5.07 explicitly reports the voting results, with both proposals receiving unanimous approval (2,221,965 FOR votes, 0 AGAINST, 0 ABSTAIN). While the filing also includes Item 1.01 (material definitive agreement) and Item 5.03 (articles amendment), the central event is the shareholder vote and its results, which is material to investors in a SPAC context as it directly affects the company's timeline to complete a business combination.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-08-12
The filing discloses results of a special meeting of stockholders held on August 11, 2026, under Item 5.07. Two proposals were voted upon: (1) approval of a 5,000-for-1 reverse stock split of common stock, which passed with 9,610,239,283 votes for and 852,596,155 against, and (2) approval of adjournment authority, which also passed. A reverse stock split is a material capital structure event affecting all shareholders and is typically material to investors assessing the registrant's financial condition and equity structure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-12
Item 5.07
This is a classic Item 5.07 disclosure of shareholder vote results from Qorvo's Annual Meeting of Stockholders held on August 11, 2026. The filing reports voting outcomes on four proposals: election of ten directors, advisory approval of named executive officer compensation, ratification of Ernst & Young LLP as independent auditor, and rejection of a shareholder proposal. The detailed voting tallies (votes for, against, abstain, and broker non-votes) for each proposal are the core content of the disclosure, making this unambiguously a shareholder_vote_results event.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-12
Item 5.07
This is a clear Item 5.07 disclosure of shareholder vote results from the Company's August 7, 2026 annual meeting. The filing presents certified voting outcomes for four proposals: election of three directors, approval of an equity compensation plan amendment, advisory vote on named executive officer compensation, and ratification of Deloitte & Touche LLP as independent auditors. The detailed vote tallies (votes for, against, abstentions, and broker non-votes) for each proposal are the core content of the disclosure.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-08-11
The 6-K discloses results of an Annual General Meeting of shareholders held on August 11, 2026, reporting adoption of five resolutions: re-election of four directors, election of a new external director (Amit Foox), extension of exculpation and indemnification letters for Revital Cohen-Tzemach, and re-appointment of the independent auditor Kost Forer Gabbay & Kasierer. This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent, reporting the outcomes of shareholder votes on governance and audit matters.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-08-11
Item 5.07
At a Special Meeting held on August 10, 2026, RYTHM shareholders approved the issuance of common stock to holders of convertible promissory notes and warrants under Nasdaq Listing Rule 5635, with 1,118,058 votes in favor, 10,049 against, and 747 abstained.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-08-11
Item 5.07
This Item 5.07 disclosure reports the results of Zeo Energy Corp.'s 2026 annual meeting of stockholders held on August 7, 2026. The filing details voting outcomes on four matters: (1) election of five directors, (2) approval of potential issuance of Class A common stock equal to or exceeding 20% pursuant to a Note Purchase Agreement with White Lion Capital LLC, (3) ratification of Tanner LLC as independent auditor, and (4) adjournment proposal. The disclosure of shareholder vote results on material matters such as director elections and dilutive equity issuances is material to investors' understanding of corporate governance and capital structure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-08-11
The filing discloses Item 5.07 results from Nexalin Technology's annual stockholder meeting held August 11, 2026, including voting outcomes on six proposals: election of five directors (all passed), approval of the 2026 Equity Incentive Plan (passed), reverse stock split authorization (passed), preferred stock authorization (failed), officer exculpation amendment (failed), and auditor ratification (passed). This is a standard shareholder vote results disclosure with material governance implications.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-10
Item 5.07
This Item 5.07 disclosure reports the results of the 2026 Annual Meeting of Stockholders held on August 6, 2026, specifically the election of five directors (Ella S. Neyland, Anthony Chereso, Alan Feldman, Michael W. Reid, and Daniel Rigby) with detailed vote tallies showing votes for, against, abstentions, and broker non-votes for each nominee. This is a textbook shareholder vote results disclosure required under Item 5.07.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-10
Item 5.07
This is a clear disclosure of shareholder voting results from LENSAR's August 4, 2026 annual meeting of stockholders, filed under Item 5.07. The filing reports results for four proposals: election of three Class III directors (Thomas B. Ellis, Richard L. Lindstrom, MD, and William J. Link, PhD), ratification of PricewaterhouseCoopers LLP as auditor, advisory approval of named executive officer compensation, and advisory vote on compensation vote frequency (approved at one-year intervals). All proposals passed. This is a material governance event affecting investor understanding of board composition and corporate oversight.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-10
Item 5.07
This Item 5.07 disclosure reports the results of OSR Health's August 7, 2026 annual stockholder meeting, including the re-election of seven directors, ratification of the independent auditor, approval of executive compensation, and authorization of additional shares. The filing presents voting tallies for each proposal, which is the core content of a shareholder vote results disclosure. These outcomes are material to investors as they confirm board composition, auditor retention, and capital structure changes.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 94%
filed 2026-08-10
Item 5.07
Shareholders approved an amendment to the Company's Articles of Association extending the deadline for completing an initial business combination from August 8, 2026 to August 8, 2027, and approved an adjournment proposal at an extraordinary general meeting held on August 4, 2026. Additionally, shareholders exercised redemption rights for 12,863,312 Class A ordinary shares, resulting in approximately $135.2 million being removed from the trust account and $15.9 million remaining.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 75%
filed 2026-08-10
EX-99.1
This is a notice and proxy statement for an extraordinary general meeting scheduled for August 20, 2026, soliciting shareholder votes on three proposals: (1) a 50-for-1 share consolidation, (2) adoption of amended memorandum and articles of association, and (3) meeting adjournment. While the document is dated August 10, 2026 (before the meeting), it is being furnished as an exhibit to a 6-K filed on August 10, 2026, and constitutes the formal disclosure of shareholder voting matters. The share consolidation is a material capital structure change affecting all shareholders. However, this is technically a pre-meeting notice rather than post-meeting results; the classification as shareholder_vote_results is the closest fit in the taxonomy for material shareholder voting disclosures, though the results themselves are not yet known at filing date.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-08-10
EX-99.1
This news release discloses the voting results from Aurora Cannabis Inc.'s Annual General Meeting of Shareholders held August 7, 2026. The exhibit provides detailed voting tallies for five board nominees (Miguel Martin, Michael Singer, Chitwant Kohli, Norma Beauchamp, and Rajesh Uttamchandani), approval of Ernst & Young LLP as auditors, and a "Say-on-Pay" advisory vote on executive compensation (82.97% FOR). This is a classic shareholder_vote_results disclosure reporting the outcomes of an annual meeting election and resolutions.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 98%
filed 2026-08-10
EX-99.1
This exhibit is a formal report of voting results from Aurora Cannabis Inc.'s annual general meeting of shareholders held on August 7, 2026, disclosing the outcomes of four shareholder votes: (1) fixing the number of directors at five, (2) election of five directors by name, (3) appointment of Ernst & Young LLP as auditors, and (4) an advisory say-on-pay vote on executive compensation. The document explicitly states it is filed "Pursuant to Section 11.3 of National Instrument 51-102 Continuous Disclosure Obligations," which is the Canadian equivalent of Item 5.07 (Results of Shareholder Votes). These governance outcomes are material to investors assessing the company's leadership and oversight structure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-10
Item 5.07
NVE Corp held its 2026 Annual Meeting on August 6, 2026, with shareholders voting on three proposals: election of seven directors, advisory approval of named executive officer compensation, and ratification of independent auditor Boulay PLLP. All three proposals passed with overwhelming majorities.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-10
Item 5.07
Modiv Industrial stockholders voted at a special meeting on August 10, 2026, approving the merger with Global Net Lease with 6,363,283 votes in favor versus 295,685 against (approximately 94% of votes cast and more than 61% of outstanding shares). Shareholders also approved a non-binding advisory vote on merger-related executive compensation and an adjournment proposal.
View raw filing on EDGAR →